CURZION PHARMACEUTICALS

curzion-pharmaceuticals-logo

Curzion Pharmaceuticals is a privately held development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, CZN001 (renamed HZN-825).

#SimilarOrganizations #Financial #More

CURZION PHARMACEUTICALS

Industry:
Biotechnology Health Care Pharmaceutical

Founded:
2019-01-01

Address:
San Diego, California, United States

Country:
United States

Total Employee:
1+

Status:
Active

Total Funding:
0


Similar Organizations

diartis-pharmaceuticals-logo

Diartis Pharmaceuticals

Diartis Pharmaceuticals is a privately held biopharmaceutical company.

g3-pharmaceuticals-logo

G3 Pharmaceuticals

G3 pharmaceuticals is a development-stage biopharmaceutical company.

harkness-pharmaceuticals-logo

Harkness Pharmaceuticals

Harkness Pharmaceuticals is a privately-held development stage biopharmaceutical company.

Investors List

new-enterprise-associates_image

New Enterprise Associates

New Enterprise Associates investment in Venture Round - Curzion Pharmaceuticals

More informations about "Curzion Pharmaceuticals"

Curzion Pharmaceuticals - PitchBook

Curzion Pharmaceuticals General Information Description. Operator of a biotechnology company based in San Diego, California. The company is engaged in the development of oral selective โ€ฆSee details»

Curzion Pharmaceuticals - Products, Competitors, Financials, โ€ฆ

Curzion Pharmaceuticals, Inc. is a privately held development-stage biopharma company that is creating an oral selective lysophosphatidic acid 1 receptor antagonist (LPAR1), CZN001 โ€ฆSee details»

Curzion Pharmaceuticals - Ownership and Business Overview

Apr 2, 2020 Curzion Pharmaceuticals, Inc. is a development-stage biopharma company, and its development-stage oral selective lysophosphatidic acid 1 receptor (LPAR1) antagonist, โ€ฆSee details»

Curzion Pharmaceuticals - Crunchbase

Organization. Curzion Pharmaceuticals . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. โ€ฆSee details»

Horizon Therapeutics plc Acquires Curzion โ€ฆ

Apr 2, 2020 This press release contains forward-looking statements, including, but not limited to, statements related to the acquisition of Curzion Pharmaceuticals, Inc. and the benefits thereof, Horizonโ€™s ...See details»

Horizon Pharma acquires Curzion Pharmaceuticals - 2020-04-02 ...

Apr 2, 2020 Curzion Pharmaceuticals Curzion Pharmaceuticals is a privately held development-stage biopharma company. Acquiring Organization: Horizon Pharma Horizon Therapeutics โ€ฆSee details»

Curzion Pharmaceuticals - Pappas Capital

Curzion Pharmaceuticals is a clinical-stage company, co-founded by Pappas Capital, focused on developing treatments for rare fibrotic diseases. The company's lead asset is a potent and โ€ฆSee details»

Curzion Pharmaceuticals, Inc.: Drug pipelines, Patents, Clinical trials ...

Jul 5, 2023 Explore Curzion Pharmaceuticals, Inc. with its drug pipeline, therapeutic area, technology platform, 1 news.See details»

CURZION PHARMACEUTICALS, INC. - Address, Director information

11 rows Curzion Pharmaceuticals, Inc. it has been 6 years 1 months, and 12 days since the company registered today. Companies of the same agent name - CORPORATION SERVICE โ€ฆSee details»

Curzion Pharmaceuticals Acquired by Horizon Therapeutics

DUBLIN -- April 2, 2020 -- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma โ€ฆSee details»

Curzion Pharmaceuticals, Inc. - RiverVest

Curzion Pharmaceuticals is developing a late-stage small molecule to treat fibrotic conditions, where significant unmet needs exist. The safety and efficacy of its in-licensed lead โ€ฆSee details»

Curzion Pharmaceuticals Inc. - BioCentury Company Profiles - BCIQ

Apr 2, 2020 Curzion Pharmaceuticals Inc. - BioCentury Company Profiles for the biopharma industrySee details»

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc.

Apr 3, 2020 Forward Looking Statements. This press release contains forward-looking statements, including, but not limited to, statements related to the acquisition of Curzion โ€ฆSee details»

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc

Apr 2, 2020 Horizon Therapeutics plc announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held development-stage biopharma company, and its โ€ฆSee details»

Horizon snaps up Curzion Pharma and its ex-Sanofi rare disease โ€ฆ

Apr 3, 2020 Horizon Therapeutics has added to its growing acquisitive pipeline with the buyout of Curzion Pharmaceuticals for just $45 million.. It gains the privately held biotechโ€™s oral โ€ฆSee details»

Curzion Pharmaceuticals - Funding, Financials, Valuation & Investors

Jan 1, 2019 Curzion Pharmaceuticals has raised 1 round. This was a Venture - Series Unknown round raised on Jan 1, 2019 . Curzion Pharmaceuticals is funded by New Enterprise Associates .See details»

Curzion Pharmaceuticals - The Lundbeck Foundation

Curzion Pharmaceuticals Curzion was developing a compound for Diffuse cutaneous systemic sclerosis (dcSSc), a rare, chronic autoimmune disease marked by fibrosis, or skin thickening, โ€ฆSee details»

Curzion Pharmaceuticals - CB Insights

Curzion Pharmaceuticals has 1 board of directors, including Johan Kördel. Name. Firm. Work History. Other Seats. Johan Kördel. Prior to founding Sound Bioventures, Johan was a Senior โ€ฆSee details»

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals

Apr 2, 2020 DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it has acquired Curzion Pharmaceuticals, Inc., a privately held โ€ฆSee details»

linkstock.net © 2022. All rights reserved